Health Care · Life Sciences Tools & Services
Thermo Fisher Scientific: revenue, profit and dividends
In fiscal 2025, Thermo Fisher Scientific had revenue of $44.6B, up 10.1% a year on average since 2015, and net income of $6.7B (15.0% of revenue). Its dividend per share has gone up 8 years in a row, to $1.72. It has 6% fewer shares than in 2015.
Revenue, fiscal 2025
average annual revenue growth since 2015 · +3.9% vs 2024
- Ticker
- TMO · NYSE
- Sector
- Health Care
- Sub-industry
- Life Sciences Tools & Services
- Headquarters
- Waltham, Massachusetts
- Founded
- 2006 (1902)
- In the S&P 500 since
- August 3, 2004
- Latest fiscal year
- 2025, ended December 31, 2025
- SEC filer
- Thermo Fisher Scientific Inc. · CIK 0000097745
Revenue and net income
Revenue went from $9.75B in 2007 to $44.6B in 2025.
Diluted earnings per share
Diluted EPS went from $1.69 in 2007 to $17.74 in 2025. Ten-year growth: 13.7% a year.
Dividends per share
Raised 8 years in a row, every year from 2018 to 2025. Ten-year growth: 11.1% a year.
Shares outstanding
6.0% fewer shares in 2025 than in 2015 (402M → 378M): buybacks outweighed new shares.
Operating cash flow, capex and free cash flow
Free cash flow (operating cash flow minus capital expenditure) was $6.29B in 2025, 14.1% of revenue.
The chart data could not be loaded. The table below has the same figures.
Year by year
| Fiscal year | Revenue | Net income | Net margin | Diluted EPS | Dividend | Shares | Operating cash flow | Capex | Free cash flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $44.6B | $6.7B | 15.0% | $17.74 | $1.72 | 378M | $7.82B | $1.52B | $6.29B |
| 2024 | $42.9B | $6.33B | 14.8% | $16.53 | $1.56 | 383M | $8.67B | $1.4B | $7.27B |
| 2023 | $42.9B | $6.0B | 14.0% | $15.45 | $1.40 | 388M | $8.41B | $1.48B | $6.93B |
| 2022 | $44.9B | $6.95B | 15.5% | $17.63 | $1.20 | 394M | $9.15B | $2.24B | $6.91B |
| 2021 | $39.2B | $7.72B | 19.7% | $19.46 | $1.04 | 397M | $9.31B | $2.52B | $6.79B |
| 2020 | $32.2B | $6.38B | 19.8% | $15.96 | $0.88 | 399M | $8.29B | $1.47B | $6.82B |
| 2019 | $25.5B | $3.7B | 14.5% | $9.17 | $0.76 | 403M | $4.97B | $926M | $4.05B |
| 2018 | $24.4B | $2.94B | 12.1% | $7.24 | $0.68 | 406M | $4.54B | $758M | $3.79B |
| 2017 | $20.9B | $2.23B | 10.6% | $5.59 | $0.60 | 398M | $4.0B | $508M | $3.5B |
| 2016 | $18.3B | $2.02B | 11.1% | $5.09 | $0.60 | 397M | $3.26B | $444M | $2.81B |
| 2015 | $17B | $1.98B | 11.6% | $4.92 | $0.60 | 402M | $2.94B | $423M | $2.52B |
| 2014 | $16.9B | $1.89B | 11.2% | $4.71 | $0.60 | 402M | $2.62B | $428M | $2.19B |
| 2013 | $13.1B | $1.27B | 9.7% | $3.48 | $0.60 | 366M | $2.01B | $282M | $1.73B |
| 2012 | $12.5B | $1.18B | 9.4% | $3.21 | $0.54 | 367M | $2.04B | $315M | $1.72B |
| 2011 | $11.6B | $1.33B | 11.5% | $3.46 | $0.00 | 385M | $1.69B | $261M | $1.43B |
| 2010 | $10.4B | $1.04B | 10.0% | $2.53 | $0.00 | 409M | $1.5B | $245M | $1.25B |
| 2009 | $9.91B | $850M | 8.6% | $2.01 | — | 423M | $1.66B | $200M | $1.46B |
| 2008 | $10.5B | $981M | 9.3% | $2.25 | — | 435M | $1.42B | $264M | $1.16B |
| 2007 | $9.75B | $748M | 7.7% | $1.69 | — | 444M | $1.48B | $176M | $1.31B |
Fiscal years, labelled by the year in which they end. US dollars; per-share figures and share counts adjusted for splits. —: not in the data.
About these figures
- Older years are as filed at the time and may predate later restatements, mergers or spin-offs. How the figures are made.
Other Life Sciences Tools & Services companies
Source: SEC EDGAR (company filings), data as of November 8, 2026. Sectors, sub-industries, headquarters and index dates: Wikipedia, CC BY-SA 4.0.